Position in SCLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$53
-$32 QoQ
Shares Held
8
+14.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SCLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026US BANCORP \DE\ holds $3,195,249,208 across 17 Drug Manufacturers - General names. SCLX ranks #17 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,357,610 | $1,248,688,948 | |
| 2 | JNJ |
Johnson & Johnson
|
2,492,186 | $609,189,945 | |
| 3 | ABBV |
AbbVie Inc.
|
2,328,944 | $506,522,029 | |
| 4 | AMGN |
Amgen Inc
|
667,057 | $234,704,003 | |
| 5 | MRK |
Merck & Co., Inc.
|
1,554,747 | $187,020,515 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
856,921 | $119,429,077 | |
| 7 | PFE |
Pfizer Inc
|
3,863,894 | $108,498,142 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
1,329,743 | $80,648,911 |
All Filings in SCLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $53 | 8 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $85 | 7 | Shares | Defined | 2026-01-30 | |
| 2025-09-30 | $1,121 | 57 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $41 | 7 | Shares | Defined | 2025-07-24 | |
| No filing history on record for this holder in this stock. | ||||||